Nimodipine-d7
(Synonyms: 尼莫地平 d7) 目录号 : GC47775
An internal standard for the quantification of nimodipine
Cas No.:1246815-36-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nimodipine-d7 is intended for use as an internal standard for the quantification of nimodipine by GC- or LC-MS. Nimodipine is an inhibitor of L-type voltage-gated calcium (Cav) channels.1 It is selective for Cav1.2 over Cav1.3 channels (IC50s = 0.139 and 2.7 µM, respectively), as well as R-, N-, and P/Q-type Cav channels at 10 µM.1,2 Nimodipine (0.72-24 nM) inhibits contractions induced by potassium, but not norepinephrine, in isolated rabbit aortic strips.3 It increases cerebral blood flow in anesthetized dogs when administered sublingually at doses ranging from 0.01 to 1 mg/kg. Nimodipine decreases necrosis of hippocampal CA1 pyramidal neurons and reduces increases in spontaneous movement and contralateral circling in a rat model of focal cerebral ischemia induced by middle cerebral artery occlusion (MCAO).4
1.Furukawa, T., Yamakawa, T., Midera, T., et al.Selectivities of dihydropyridine derivatives in blocking Ca2+ channel subtypes expressed in Xenopus oocytesJ. Pharmacol. Exp. Ther.291(2)464-473(1999) 2.Xu, W., and Lipscombe, D.Neuronal Cav1.3ɑ1 L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridinesJ. Neurosci.21(16)5944-5951(2001) 3.Kazda, S., and Towart, R.Nimodipine: A new calcium antagonistic drug with a preferential cerebrovascular actionActa Neurochir. (Wien)63(1-4)259-265(1982) 4.Babu, C.S., and Ramanathan, M.Post-ischemic administration of nimodipine following focal cerebral ischemic-reperfusion injury in rats alleviated excitotoxicity, neurobehavioural alterations and partially the bioenergeticsInt. J. Dev. Neurosci.29(1)93-105(2011)
| Cas No. | 1246815-36-0 | SDF | |
| 别名 | 尼莫地平 d7 | ||
| Canonical SMILES | CC1=C(C(OCCOC)=O)C(C2=CC=CC([N+]([O-])=O)=C2)C(C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)=C(C)N1 | ||
| 分子式 | C21H19D7N2O7 | 分子量 | 425.5 |
| 溶解度 | Chloroform: slightly soluble,Methanol: slightly soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3502 mL | 11.7509 mL | 23.5018 mL |
| 5 mM | 0.47 mL | 2.3502 mL | 4.7004 mL |
| 10 mM | 0.235 mL | 1.1751 mL | 2.3502 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。